Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.19.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating Activities:    
Net loss $ (13,201) $ (9,050)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 3] 192 220
Stock-based compensation [note 6 [c] and note 6 [d]] 917 588
Cumulative adjustment on adoption of lease standard (3)  
Changes in operating assets and liabilities:    
Amounts receivable   (16)
Prepaid expenses and other assets 597 212
Accounts payable 430 245
Accrued liabilities other (320) 317
Accrued clinical liabilities (462) (210)
Accrued compensation 39 613
Other liabilities 9 (1)
Net cash used in operating activities (11,802) (7,082)
Financing Activities:    
Proceeds from the sale of preferred stock, common stock and warrants, net of issuance costs   12,193
Proceeds from exercise of warrants, net of issuance costs 4,199 1,274
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs 423 1,280
Net cash provided by financing activities 4,622 14,747
Investing Activities:    
Purchase of property and equipment (52) (36)
Proceeds on disposal of assets   10
Purchase of investments (25) (1,390)
Proceeds from maturities of investments 5,114  
Net cash provided by (used in) investing activities 5,037 (1,416)
Effect of exchange rate changes on cash 3  
Net increase (decrease) in cash, cash equivalents and restricted cash (2,140) 6,249
Cash, cash equivalents and restricted cash at beginning of the period 9,565 5,556
Cash, cash equivalents and restricted cash at end of the period $ 7,425 $ 11,805